In partnership with
Dear Readers,
What sounds like science fiction is becoming reality: With Isomorphic Labs, Google DeepMind is entering the medical arena with the goal of curing all diseases. Powered by generalist AI, the platform designs drugs in weeks instead of years—a paradigm shift for the entire pharmaceutical industry. The first clinical trials are already underway. But as fascinating as this technological leap is, it raises what is perhaps the most important question of our time. If we manage to defeat Alzheimer's, cancer, and aging itself, who will decide who gets access to this power?
This development marks a turning point not only in medicine, but also in the relationship between technology, ethics, and power. We are on the threshold of a future in which AI will rewrite our destiny.
In Today’s Issue:
Google's AI drug discovery lab is now moving into human clinical trials
Figure AI reveals its strategy to put humanoid robots in factories before homes
ChatGPT solved a visual puzzle that seems impossible for a machine
A new Claude model is reportedly going head-to-head with the best AIs in math
And more AI goodness…
All the best,
Google is going to cure all diseases
“One day we hope to be able to say — well, here’s a disease, and then click a button and out pops the design for a drug to address that disease,” Murdoch said. “All powered by these amazing AI tools.”
The TLDR
Isomorphic Labs, Google DeepMind's AI-driven drug discovery company, is preparing to launch its first human clinical trials. Leveraging the technology behind AlphaFold, Isomorphic's platform models complex biological systems to design novel drugs in a fraction of the traditional time. This move from digital modeling to real-world clinical testing marks a critical step in the company's ambitious mission to use AI to find cures for diseases like cancer and Alzheimer's.
Isomorphic Labs, Google DeepMind's AI biology lab, wants nothing less than to defeat all diseases. With a revolutionary platform that models biological systems as precisely as a chess computer models the game, the company is now launching its first clinical trials. The AI develops drugs in weeks instead of years – a quantum leap for medicine.
CEO Demis Hassabis speaks of a turning point: “We are on the cusp of a new science where AI and biology are merging.” If the technology delivers on its promise, Alzheimer's, cancer, and even the aging process itself could soon be treatable.
For the AI community, this is more than a medical breakthrough. It is proof of how much generalist AI is already impacting the most complex areas of life – with enormous potential and huge ethical questions.
Why it matters: This technology could radically improve the quality of life for billions of people and reinvent medicine. But it raises the central question: Who should control AI that prolongs life?
Sources:
Ad
Emergent: World’s First Agentic AI Product Builder
Emergent has radically simplified app development for non-coders. This platform is the world's first Agentic AI Product Builder which writes full stack code for you with serious security.
It has specialized agents for each task like backend, frontend, images, security, scalability - its basically like having a team of software developers.
All you need is a brief description of the idea, and a few minutes later you have a working product with auth, db, payments - all configured, ready to ship
In The News
Figure AI's "Workforce First" Strategy
According to CEO Brett Adcock, Figure AI is prioritizing the deployment of its humanoid robots in the industrial workforce, where he says they can command a significantly higher price, but expects the robots to be available for home use within single-digit years.
AI Model Solves Extreme Visual Puzzle
In a remarkable demonstration of its visual reasoning capabilities, ChatGPT o3-pro successfully identified a 1965 quote by I. J. Good from a photo of a handwritten note that had been ripped into four strips, placed in reverse order, and rotated in alternating directions.
New Claude Model Reportedly Matches Top-Tier AI in Math
According to early reports from testers, Anthropic's new model, "Claude Neptune v3," is demonstrating a significant leap in mathematical reasoning. The model is said to be consistently solving complex math problems at a level comparable to elite models like o3 Pro and the much-discussed "Kingfall."
Graph of the Day
II-Medical-32B-Preview shows insane medical performance. Its open source, free and outperforming the competition.
AI is reshaping investment portfolios
Private markets are gaining massive importance thanks to AI – traditional leading indicators such as inflation and GDP are fading into the background. Tech giants are pumping billions into data centers and AI research, which is supporting the S&P 500 and energy markets. This realignment is challenging the classic 60/40 strategy and changing business models along the entire value chain – from infrastructure and capital allocation to the stability of the financial system.
Bank of England: AI could trigger systemic market crash
The Bank of England warns that autonomous AI trading algorithms could promote market distortions, volatility triggers, and even collusion—especially if many players use the same models. Added to this are risks from data manipulation, cyber threats, and concentration among a few AI providers
Equifax sees AI cut bad debt by 15–20%
Fintech data provider Equifax reports that sustainable use of AI improves default risk by 15–20% and acceptance rates by up to 10%. At the same time, experts warn of model drift, distortions, and a lack of explainability—transparency is essential for compliance with regulatory requirements.
Question of the Day
Tweet of the Day
Sponsored By Vireel.com
Vireel is the easiest way to get thousands or even millions of eyeballs on your product. Generate 100's of ads from proven formulas in minutes. It’s like having an army of influencers in your pocket, starting at just $3 per viral video.
